NLTX News and Press, Neoleukin Therapeutics Inc. From 11/09/20

Neoleukin Therapeutics (NLTX): Q3 GAAP EPS of -$0.04 beats by $0.19.Cash and cash equivalents of $201.2MPress Release For further details see: Neoleukin Therapeutics EPS beats by $0.19

- NL-201 IND submission anticipated by year end 2020 - - Clinical Trial Notification application submitted in Australia - -Ended 3 rd quarter with $ 201.2 million in cash and cash equivalents - SEATTLE, Nov. 0...

- I ntranasal administration of NL-CVX1 protects hamsters from lethal SARS-CoV-2 infection – - Designed to r esist viral mutational escape b y mimicking the natural target of the s pike protein - ...

SEATTLE, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of a preclinical data abstra...

SEATTLE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced the appointment of Martin Babler, ...

SEATTLE, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced that Jonathan Drachman, M.D., Chie...

Neoleukin Therapeutics, Inc. (NLTX) Q2 2020 Earnings Conference Call August 12, 2020 4:30 PM ET Company Participants Julie Rathbun - Communications Jonathan Drachman - Chief Executive Officer Bob Ho - Chief Financial Officer Daniel-Adriano Silva - Head of Research Carl Walkey...

Neoleukin Therapeutics (NASDAQ: NLTX ) : Q2 GAAP EPS of -$0.20 misses by $0.04 . More news on: Neoleukin Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

NL-201 IND submission anticipated during fourth quarter of 2020 Recent financing raises $71.4M in net proceeds to enable broad NL-201 clinical plan and product pipeline development into 2023 Company to host Conference Call Today, August 12, 2020 at 1:30 p.m. Pacific / 4:30 p.m. East...

SEATTLE, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design  de novo  protein therapeutics, today announced that management will participate in...